Skip to main content
SpringerLink
Log in

Migraine and Functional Impairment

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Migraine is a leading cause of disability worldwide; approximately half of those affected have such severe attacks that they cannot function normally in routine daily activities. Research is beginning to focus upon the burden of migraine between attacks, referred to as interictal burden. This burden encompasses worry and expectation of future attacks that consequently may be associated with limitations in social and family interactions, as well as work capacity.

This review aims to increase physician awareness of the degree and scope of functional impairment associated with migraine. Physicians are in a position to assess the true impact of migraine in their patients using techniques such as open-ended questions during visits, and paper-based migraine assessment tools such as the Migraine Disability Assessment questionnaire. Eliciting such information on interictal burden may help the physician prescribe the most appropriate therapy based on their patients’ degree of impairment. This article also describes the instruments most widely used for measuring migraine-related functional impairment, summarizes studies assessing the effects of migraine on indicators of health-related quality of life and presents data on how preventive migraine treatment may beneficially influence migraine-related functional impairment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I

Similar content being viewed by others

References

  1. Leonardi M, Steiner TJ, Scher AT, et al. The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005; 6: 429–40

    Article  PubMed  Google Scholar 

  2. Dowson A, Jagger S. The UK Migraine Patient Survey: quality of life and treatment. Curr Med Res Opin 1999; 15: 241–53

    Article  PubMed  CAS  Google Scholar 

  3. Dahlof CGH, Dimenas E. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia 1995; 15: 31–6

    Article  PubMed  CAS  Google Scholar 

  4. Hahn SR, Lipton RB, Sheftell FD, et al. Healthcare provider-patient communication and migraine assessment: results of the American Migraine Communication Study (AMCS) phase II. Curr Med Res Opin 2008; 24: 1711–8

    Article  PubMed  Google Scholar 

  5. Lipton RB, Bigal ME, Diamond M, et al., American Migraine Prevalence and Prevention (AMPP) Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68: 343–9

    Article  PubMed  CAS  Google Scholar 

  6. Brandes JL. Global trends in migraine care: results from the MAZE survey. CNS Drugs 2002; 16 Suppl. 1: 13–8

    Article  Google Scholar 

  7. Breslau J, Davis GC. Migraine, physical health and psychiatric disorder: a prospective epidemiologic study in young adults. J Psychiat Res 1993; 27: 211–21

    Article  PubMed  CAS  Google Scholar 

  8. Dueland AN, Leira R, Burke TA, et al. The impact of migraine on work, family, and leisure among young women: a multinational study. Curr Med Res Opin 2004; 20: 1595–604

    Article  PubMed  Google Scholar 

  9. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993; 33: 29–35

    Article  PubMed  CAS  Google Scholar 

  10. Hawkins K, Wang S, Rupnow MFT. Indirect cost burden of migraine in the United States. J Occup Environ Med 2007; 49: 368–74

    Article  PubMed  Google Scholar 

  11. Bussone G, Usai S, Grazzi L, et al. Disability and quality of life in different primary headaches: results from Italian studies. Neurol Sci 2004; 25Suppl. 3: S105–7

    Article  PubMed  Google Scholar 

  12. Lipton RB, Bigal ME, Kolodner K, et al. The family impact of migraine: population-based studies in the USA and UK. Cephalalgia 2003; 23: 429–40

    Article  PubMed  CAS  Google Scholar 

  13. Linde M, Dahlof C. Attitudes and burden of disease among self-considered migraineurs: a nation-wide populationbased survey in Sweden. Cephalagia 2004; 24: 455–65

    Article  CAS  Google Scholar 

  14. Asmundson GJG, Norton PJ, Veloso F. Anxiety, sensitivity and fear of pain in patients with recurring headaches. Behav Res Ther 1999; 37: 703–13

    Article  PubMed  CAS  Google Scholar 

  15. Freitag FG. The cycle of migraine: patients’ quality of life during and between migraine attacks. Clin Ther 2007; 29: 939–49

    Article  PubMed  Google Scholar 

  16. Brandes JL. The migraine cycle: patient burden of migraine during and between migraine attacks. Headache 2008; 48: 430–41

    Article  PubMed  Google Scholar 

  17. Thomas K, Harvey D. New survey reveals worrying between attacks can extend suffering for migraineurs, 2006 Jun 8 [media release online]. Available from URL: http://www.orthomcneilneurologics.com/ortho-mcneilneurologics/pages/news_release_060806_1.jsp [Accessed 2009 Nov 2]

  18. Lipton RB, Stewart WF, Sawyer J, et al. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 2001; 41: 854–61

    PubMed  CAS  Google Scholar 

  19. Pryse-Phillips W. Evaluating migraine disability: the headache impact test instrument in context. Can J Neurol Sci 2002; 29 Suppl. 2: 11–5

    Google Scholar 

  20. Jacobson GP, Ramadan NM, Norris L, et al. Headache Disability Inventory (HDI): short-term test-retest reliability and spouse perceptions. Headache 1995; 35: 534–49

    Article  PubMed  CAS  Google Scholar 

  21. Dahlof CG. Measuring disability and quality of life in migraine. Drugs Today 2003; 39Suppl. D: 17–23

    PubMed  Google Scholar 

  22. Revicki DA. Health related quality of life in the evaluation of medical therapy for chronic illness. J Fam Pract 1989; 29: 377–80

    PubMed  CAS  Google Scholar 

  23. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): I. Conceptual framework and item selection. Med Care 1992; 30: 473–83

    Article  PubMed  Google Scholar 

  24. Martin BC, Pathak DS, Sharfman MI, et al. Validity and reliability of the migraine-specific quality of life questionnaire (MSQ version 2.1). Headache 2000; 40: 204–15

    Article  PubMed  CAS  Google Scholar 

  25. Buse DC, Bigal ME, Rupnow MFT, et al. The Migraine Interictal Burden Scale (MIBS): results of a populationbased validation study [abstract no. S05.003]. 59th Annual Meeting of the American Academy of Neurology; 2007 Apr 28–May 5; Boston (MA)

  26. Dueland AN, Leira R, Cabelli ST. The impact of migraine on psychological well-being of young women and their communication with physicians about migraine: a multinational study. Curr Med Res Opin 2005; 21: 1297–305

    Article  PubMed  Google Scholar 

  27. Martin LR, Jahng KH, Golin CE, et al. Physician facilitation of patient involvement in care: correspondence between patient and observer reports. Behav Med 2003; 28: 159–64

    Article  PubMed  Google Scholar 

  28. Lipton RB, Hahn SR, Cady RK, et al. In-office discussions of migraine: results from the American Migraine Communication Study. J Gen Intern Med 2008; 23: 1145–51

    Article  PubMed  Google Scholar 

  29. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd ed. Cephalalgia 2004; 24Suppl. 1: 1–15

    Google Scholar 

  30. Ramadan NM. Migraine headache prophylaxis: current opinions and advances on the horizon. Curr Neurol Neurosci Rep 2006; 6: 95–9

    Article  PubMed  CAS  Google Scholar 

  31. Silberstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. Neurology 2000; 54: 1553

    Article  PubMed  CAS  Google Scholar 

  32. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. St. Paul (MN): American Academy of Neurology, 2000

    Google Scholar 

  33. Brandes JL. Practical use of topiramate for migraine prevention. Headache 2005; 45Suppl. 1: S66–73

    Article  PubMed  Google Scholar 

  34. Arulmozhi DK, Veeranjaneyulu A, Bodhankar SL. Migraine: current therapeutic targets and future avenues. Curr Vasc Pharmacology 2006; 4: 117–28

    Article  CAS  Google Scholar 

  35. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004; (2): CD003225

  36. Ramadan M, Silberstein SD, Freitag FB, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine [online]. Available from URL: http://www.aan.com/professionals/practice/pdfs/gl0090.pdf [Accessed 2009 Sep 17]

  37. Loder E, Biondi D. General principles of migraine management: the changing role of prevention. Headache 2005; 45Suppl. 1: S33–47

    Article  PubMed  Google Scholar 

  38. Blocadren (timolol maleate) tablets label [online]. Available from URL: http://www.merck.com/product/usa/pi_circulars/b/blocadren/blocadren_pi.pdf [Accessed 2008 Mar 17]

  39. Inderal (propranolol hydrochloride) tablets label [online]. Available from URL: http://www.wyeth.com/content/ShowLabeling.asp?id=106 [Accessed 2008 Mar 17]

  40. Brandes JL, Saper JR, Diamond M, et al., MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291: 965–73

    Article  PubMed  CAS  Google Scholar 

  41. Silberstein SD, Neto W, Scmitt J, et al., MIGR-001 Study Group. Topiramate in migraine prevention: results from a large controlled trial. Arch Neurol 2004; 61: 490–5

    Article  PubMed  Google Scholar 

  42. Silberstein SD, Lipton RB, Dodick DW, et al., Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170–80

    Article  PubMed  Google Scholar 

  43. Silberstein S, Loder E, Forde G, et al. The impact of migraine on daily activities: effect of topiramate compared with placebo. Curr Med Res Opin 2006; 22: 1021–9

    Article  PubMed  CAS  Google Scholar 

  44. Brandes JL, Kudrow DB, Rothrock JF, et al. Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clin Proc 2006; 81: 1311–9

    Article  PubMed  CAS  Google Scholar 

  45. Diamond M, Dahlöf C, Papadopoulos G, et al. Topiramate improves health-related quality of life when used to prevent migraine. Headache 2005; 45: 1023–30

    Article  PubMed  Google Scholar 

  46. Dodick DW, Silberstein SD, Saper J, et al. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache 2007; 47: 1398–408

    Article  PubMed  Google Scholar 

  47. Topamax® (topiramate) tablets label [online]. Available from URL: http://www.topamax.com/topamax/tools-resourcesprescribing-information.html [Accessed 2008 Mar 17]

  48. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52: 281–6

    Article  PubMed  CAS  Google Scholar 

  49. Freitag FG, Collins SD, Carlson HA, et al., Depakote ER Migraine Study Group. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002; 58: 1652–9

    Article  PubMed  CAS  Google Scholar 

  50. Depakote (divalproex sodium) delayed-release tablets label [online]. Available from URL: http://www.depakoteer.com/depakoteer/patient/migraines/prescribing-information.jsp [Accessed 2008 Mar 17]

Download references

Acknowledgements

Editorial assistance was provided by Ann T. Yeung, PhD (Phase Five Communications Inc., New York, NY, USA) with funding from Ortho-McNeil Neurologics Inc. (Titusville, NJ, USA).

Dr Brandes received no compensation for the preparation of this manuscript. Dr Brandes has received grants, research, and educational support or served as a consultant to Merck, GlaxoSmithKline, UCB Pharma, Pfizer, Allergan, Johnson and Johnson, AstraZeneca, Bristol-Myers Squibb, Winston Laboratories, sanofi-aventis, Elan Pharmaceuticals, Forest Laboratories, Novartis, Endo, Pozen, Vernalis, Ortho-McNeil, Advanced Bionics, MedPointe Pharmaceuticals and Aradigm Corp.

Author information

Authors and Affiliations

  1. Saint Thomas Health Services, Nashville Neuroscience Group, Department of Neurology, Vanderbilt University School of Medicine, 300 Twentieth Ave. N, Suite 603, Nashville, Tennessee, 37203, USA

    Jan Lewis Brandes M.D.

Authors
  1. Jan Lewis Brandes M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan Lewis Brandes M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brandes, J.L. Migraine and Functional Impairment. CNS Drugs 23, 1039–1045 (2009). https://doi.org/10.2165/11530030-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11530030-000000000-00000

Keywords

Search

Navigation